Roche Holding AG Stock Börse Stuttgart

Equities

RHO

CH0012032113

Pharmaceuticals

Delayed Börse Stuttgart 09:43:21 2019-06-28 am EDT 5-day change 1st Jan Change
245 EUR -0.08% Intraday chart for Roche Holding AG -2.62% +15.68%

Financials

Sales 2024 * 60.04B 65.97B 61.48B Sales 2025 * 63.83B 70.14B 65.36B Capitalization 178B 196B 182B
Net income 2024 * 13.31B 14.63B 13.63B Net income 2025 * 14.75B 16.21B 15.11B EV / Sales 2024 * 3.21 x
Net Debt 2024 * 14.24B 15.65B 14.58B Net Debt 2025 * 8.17B 8.97B 8.36B EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
11.8 x
Employees -
Yield 2024 *
4.4%
Yield 2025 *
4.55%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
221 CHF
Average target price
279.4 CHF
Spread / Average Target
+26.42%
Consensus